SecBot SecBot
425 ·Filed Nov 9, 2026

TCGX

TCGX Acquisition Corp.
NEUTRAL
Impact 2/10
Horizonweeks Processed7d 17h ago SEC0001193125-26-452777
Rule 425 M&A communications
Actionable Insight • Neutral

Monitor for the public filing of the S-4 registration statement and the shareholder vote date, which are the next material milestones for the deal. The chairman appointment has no standalone trading implications.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$10.05
T+0 close · Nov 9, 2026 · via day close
Latest settled
−0.50%
T+5 · $10.00
Vs SPY
+1.20%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $10.05entry
  2. T+1 · 7d ago −0.10%α +0.27% · $10.04
  3. T+5 · 19h ago −0.50%α +1.20% · $10.00
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TriGemX Bio appointed Daniel Lynch as Chairman of its Board, effective immediately and continuing post-merger with TCGX. This is a routine governance update in the ongoing SPAC merger process, with no changes to deal terms, financials, or timeline.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Daniel Lynch appointed Chairman of TriGemX Bio Board, will remain Chairman after the business combination closes
  • Lynch is a veteran biotech executive, former CEO/CFO of ImClone Systems, current Executive Venture Partner at GV
  • No changes to deal terms, valuation, PIPE, or expected Q1 2027 closing timeline
  • Elismetrep Phase 3 trial results still anticipated in mid-2027
  • Draft S-4 registration statement remains confidentially submitted; no public filing yet

Financial Impact

No financial impact; appointment of a board chairman with no compensation or deal terms disclosed

Risk Factors

  • No new information on deal completion risk, shareholder approval, or redemptions
  • Forward-looking statements about elismetrep Phase 3 timeline remain subject to clinical trial risks

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-452777
Document: 0001193125-26-452777-index-headers.html0001193125-26-452777
Document: 0001193125-26-452777-index.html0001193125-26-452777
Document: 0001193125-26-452777.txt0001193125-26-452777

Track record

9 reports on TCGX

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +1.20% at T+5 after the Oct 19, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $10.00 Now $10.00 0.00% settles Nov 24
  2. Nov 16, 2026today SC 13G Neutral 3/10 Entry $10.00 Now $10.00 0.00% settles Nov 24
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $10.01 Now $10.00 −0.10% settles Nov 23
  4. Nov 9, 20267d ago 425 Neutral 2/10 Viewing Entry $10.05 to $10.00 Now $10.00 −0.50% ▼ −0.50% +1.20% vs SPY
  5. Nov 2, 202614d ago 425 Neutral 3/10 Entry $10.03 to $10.04 Now $10.00 −0.30% ▲ +0.10% +0.69% vs SPY
  6. Oct 19, 202628d ago 425 Neutral 4/10 Entry $10.01 to $10.12 Now $10.00 −0.10% ▲ +1.10% +1.07% vs SPY
  7. Oct 19, 202628d ago 425 Bullish 6/10 Entry $10.01 to $10.12 Now $10.00 −0.10% ▲ +1.10% +1.07% vs SPY
  8. Oct 19, 202628d ago 425 Bullish 7/10 Entry $10.02 to $10.14 Now $10.00 −0.20% ▲ +1.20% +1.34% vs SPY
  9. Oct 19, 202628d ago 8-K Bullish 7/10 Entry $10.02 to $10.14 Now $10.00 −0.20% ▲ +1.20% +1.34% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 7h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026